secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-09-15T23:59:59+00:00
Accession:  0001178913-25-003329
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion regains Nasdaq compliance with $9.4M equity after capital raise
------------------------------------------------------------------------

- Issued 450,000 shares to sponsor upon converting $1.8M of convertible note at $4.00/share; remaining $1.6M outstanding.
- Shareholders' equity rose to ~$9.4M from -$0.7M at July 31, 2025, after four transactions.
- Company affirms compliance with Nasdaq Capital Market equity requirement of $2.5M and expects long-term compliance.
- Gross proceeds from September 2025 public offering: ~$6.0M from sale of shares/pre-funded warrants and warrants.
- Warrant exercise inducement in August 2025 generated ~$1.8M gross proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003329/0001178913-25-003329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003329/zk2533784.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-003329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer